Drugs Affecting Lipid Metabolism

Risks Factors and Future Directions

Antonio M. Gotto Jr., Rodolfo Paoletti, Louis C. Smith, Alberico L. Catapano (Herausgeber)

Buch | Softcover

710 Seiten

2011 | Softcover reprint of the original 1st ed. 1996
Springer (Verlag)
978-94-010-6625-9 (ISBN)

Artikel merken

Even a brief scan of the table of contents of the present volume is enough to disclose the diversity of research interests and opinions in the field of lipidology. It is precisely this diversity that is the strength of our field and that was showcased by the XII International Symposium of DRUGS AFFECTING LIPID METABOLISM (DALM). The papers published here from these proceedings may be divided into three categories: those that define-and refine---our understanding ofthe clinical benefit of aggressive lipid management, those that develop our knowledge of ris!. assessment, and those that discuss the genetic, bio~hemical, and biophysical mechanisms underlying the pathology of coronary heart disease. On the clinical front, further analysis of the results of the Scandinavian Simvastatin Survival Study (4S) has indicated the cost-effectiveness of therapy in patients with established coronary heart disease. The West of Scotland Coronary Prevention Study (WOSCOPS), whose methodology was described at the DALM XII symposium, has demonstrated in a mostly primary-prevention population what 4S demonstrated for secondary prevention the year before: aggressive lipid-regulating therapy reduces coronary heart disease morbidity and mortality rates without concurrently increasing mortality from noncardiovascular causes. In the future, important considerations will be to develop protocols that maximize benefit in groups underrepresented in traditional clinical research for example, women and the elderly-and to improve compliance to existing treatment regimens. Furthermore, antioxidant, omega-3 fatty acid, and gene therapies warrant further investigation.

Preface xiii.- I. VASCULAR PROTECTION: BIOLOGY AND PATHOLOGY.- II. LIPID RISK FACTORS.- III. RECOMBINANT GENETIC MODELS AND GENE THERAPY OF DYSLIPOPROTEINEMIA.- IV. TREATMENT STRATEGIES FOR SPECIFIC POPULATIONS.- V. CONTROL OF RISK FACTORS.- VI. MODIFIED LIPOPROTEINS AND LIPOPROTEIN METABOLISM.- VII. THE EFFECTS OF OMEGA-3 FATTY ACIDS ON LIPID METABOLISM.

Reihe/Serie	Medical Science Symposia Series ; 10
Mitarbeit	Chef-Herausgeber: Ann S. Jackson
Zusatzinfo	710 p.
Verlagsort	Dordrecht
Sprache	englisch
Maße	160 x 240 mm
Themenwelt	Medizinische Fachgebiete ► Innere Medizin ► Diabetologie
	Medizinische Fachgebiete ► Innere Medizin ► Endokrinologie
	Medizinische Fachgebiete ► Innere Medizin ► Kardiologie / Angiologie
	Studium ► 1. Studienabschnitt (Vorklinik) ► Biochemie / Molekularbiologie
	Studium ► Querschnittsbereiche ► Epidemiologie / Med. Biometrie
ISBN-10	94-010-6625-6 / 9401066256
ISBN-13	978-94-010-6625-9 / 9789401066259
Zustand	Neuware